Physician profile
Jonathan Lurz
NPI 1619599958
$6,369.07
in general payments reported to CMS, 2019-2025
20 companies · $1,471 in 2025
The $1,471 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.55 · 2022: $1,199 · 2023: $1,764 · 2024: $1,877 · 2025: $1,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,104 · Education: $8.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,104.34 |
| Education | $8.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,013.18 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,008.96 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $805.63 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $499.71 | 2023-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $422.81 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $410.55 | 2022-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $399.06 | 2022-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $338.40 | 2023-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $330.84 | 2022-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $263.45 | 2022-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $235.49 | 2022-2025 | Uzedy |
| Collegium Pharmaceutical, INC. | $154.28 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $144.88 | 2024-2025 | Cobenfy |
| Noven Pharmaceuticals, INC. | $111.16 | 2024 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $71.42 | 2022-2024 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $49.52 | 2024-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $39.49 | 2022 | |
| Corium, LLC | $34.73 | 2023 | Azstarys |
| Owp Pharmaceuticals, INC. | $20.11 | 2025 | Subvenite |
| Merck Sharp & Dohme LLC | $15.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lurz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.